Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

Similar articles for PubMed (Select 24174369)

1.

Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.

Andrisani G, Marzo M, Celleno L, Guidi L, Papa A, Gasbarrini A, Armuzzi A.

Eur Rev Med Pharmacol Sci. 2013 Oct;17(20):2831-6.

2.

[Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].

Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A, Royo Escosa V, Bosque López MJ.

Gastroenterol Hepatol. 2011 Oct;34(8):546-50. doi: 10.1016/j.gastrohep.2011.04.003. Epub 2011 Jun 12. Spanish.

PMID:
21665330
3.

Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.

Broge T, Nguyen N, Sacks A, Davis M.

Inflamm Bowel Dis. 2013 Apr;19(5):E75-7. doi: 10.1097/MIB.0b013e3182802c93. No abstract available.

PMID:
23435403
4.

Infliximab-induced psoriasis during therapy for Crohn's disease.

Steinwurz F, Denadai R, Saad-Hossne R, Queiroz ML, Teixeira FV, Romiti R.

J Crohns Colitis. 2012 Jun;6(5):610-6. doi: 10.1016/j.crohns.2011.12.007. Epub 2012 Jan 26.

PMID:
22398095
5.

Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.

Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, Bermejo F.

J Crohns Colitis. 2012 Jun;6(5):518-23. doi: 10.1016/j.crohns.2011.10.007. Epub 2011 Nov 13.

PMID:
22398059
6.

[Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].

Avila Alvarez A, García-Alonso L, Solar Boga A, García-Silva J.

An Pediatr (Barc). 2009 Mar;70(3):278-81. doi: 10.1016/j.anpedi.2008.11.013. Epub 2009 Feb 8. Spanish.

7.

Ustekinumab: moving the target from psoriasis to Crohn's disease.

Settesoldi A, Coppola M, Rogai F, Annese V.

Expert Rev Gastroenterol Hepatol. 2014 Jan;8(1):5-13. doi: 10.1586/17474124.2014.850414. Epub 2013 Nov 25. Review.

PMID:
24410468
8.

Update on ustekinumab for the treatment of Crohn's disease.

Leung Y, Panaccione R.

Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013. Review.

PMID:
25110262
9.
10.

[How I treat....psoriasis comorbidities by adalimumab (Humira) anti-TNFalpha].

Piérard-Franchimont C, Henry F, Szepetiuk G, Piérard GE.

Rev Med Liege. 2010 Oct;65(10):545-8. French.

PMID:
21128358
11.

The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.

Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD.

J Crohns Colitis. 2014 Jun;8(6):480-8. doi: 10.1016/j.crohns.2013.10.013. Epub 2013 Nov 21.

PMID:
24268978
12.

Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.

Iborra M, Beltrán B, Bastida G, Aguas M, Nos P.

J Crohns Colitis. 2011 Apr;5(2):157-61. doi: 10.1016/j.crohns.2010.11.001. Epub 2010 Dec 7.

PMID:
21453886
13.

[Psoriasis induced by infliximab].

Fernandes IC, Torres T, Sanches M, Velho G, Lago P, Selores M.

Acta Med Port. 2011 Dec;24 Suppl 3:709-12. Epub 2011 Dec 31. Portuguese.

14.

Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.

Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR.

J Am Acad Dermatol. 2012 Nov;67(5):e179-85. doi: 10.1016/j.jaad.2011.05.038. Epub 2011 Jul 14.

PMID:
21752492
15.

First case report of adalimumab-induced psoriasis in Crohn's disease.

Harris MD, Richards R.

Am J Gastroenterol. 2009 Mar;104(3):792-3. doi: 10.1038/ajg.2008.101. Epub 2009 Feb 3. No abstract available.

PMID:
19262532
16.

Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab.

Medkour F, Babai S, Chanteloup E, Buffard V, Delchier JC, Le-Louet H.

Gastroenterol Clin Biol. 2010 Feb;34(2):140-1. doi: 10.1016/j.gcb.2009.10.021. Epub 2010 Feb 6. No abstract available.

17.

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S.

Gut. 2014 Apr;63(4):567-77. doi: 10.1136/gutjnl-2012-302853. Epub 2013 Mar 6.

PMID:
23468464
18.

Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn's disease.

Kawashima K, Ishihara S, Yamamoto A, Ohno Y, Fukuda K, Onishi K, Kinoshita Y.

Inflamm Bowel Dis. 2013 Mar;19(3):E33-4. doi: 10.1002/ibd.22922. No abstract available.

PMID:
22508420
19.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
20.

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

Puig L, Morales-Múnera CE, López-Ferrer A, Geli C.

Dermatology. 2012;225(1):14-7. doi: 10.1159/000339864. Epub 2012 Aug 10. Review.

PMID:
22890275
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk